Abstract
Lentiviral vectors enter cells with high efficiency and deliver stable transduction through integration into host chromosomes, but their preference for integration within actively transcribing genes means that insertional mutagenesis following disruption of host proto-oncogenes is a recognized concern. We have addressed this problem by combining the efficient cell and nuclear entry properties of HIV-1-derived lentiviral vectors with the integration profile benefits of Sleeping Beauty (SB) transposase. Importantly, this integration enzyme does not exhibit a preference for integration within active genes. We generated integrase-deficient lentiviral vectors (IDLVs) to carry SB transposon and transposase expression cassettes. IDLVs were able to deliver transient transposase expression to target cells, and episomal lentiviral DNA was found to be a suitable substrate for integration via the SB pathway. The hybrid vector system allows genomic integration of a minimal promoter-transgene cassette flanked by short SB inverted repeats (IRs) but devoid of HIV-1 long terminal repeats (LTRs) or other virus-derived sequences. Importantly, integration site analysis revealed redirection toward a profile mimicking SB-plasmid integration and away from integration within transcriptionally active genes favored by integrase-proficient lentiviral vectors (ILVs).
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1197-1204 |
| Number of pages | 8 |
| Journal | Molecular Therapy |
| Volume | 17 |
| Issue number | 7 |
| DOIs | |
| State | Published - 2009 |
Bibliographical note
Funding Information:Research at the Institute of Child Health and Great Ormond Street Hospital for Children NHS Trust benefits from R&D funding received from the NHS Executive. C.A.V. is the recipient of a Child Health Research Appeal Trust award. A.J.T. is a Senior Wellcome Trust fellow. W.Q. is a Leukaemia Research Fund Senior Clinical Lecturer. This work was also supported by the Deutsche Forschungsgemeinschaft DFG (SPP1230).
